6.3.1.3 Dipeptidylpeptidase-4 inhibitors (gliptins)
Position Statement: DPP-4 inhibitors (gliptins) in the management of Type 2 Diabetes
Sitagliptin is the first line/preferred cost-effective gliptin. Sitagliptin is first line for all eligible patients/new initiations. Where existing patients are prescribed a different gliptin, and ongoing prescribing of a gliptin is indicated following diabetes review, switch to generic sitagliptin if appropriate.
Linagliptin is the second line gliptin to be used only after sitagliptin has been tried, or if eGFR <45ml/min/1.73m2.
Expand All / Expand All (incl. cost)
Documents
-
Primary Care
-
Secondary Care
-
Primary and Secondary Care
Uploaded By:
Renewal: 02/2027
Approved: 12/2024
Last Reviewed: 12/2024
Document linked to:
| Drug | Section |
|---|---|
| Linagliptin |
6.3.1.3 Dipeptidylpeptidase-4 inhibitors (gliptins)
|
| Sitagliptin (Generic) |
6.3.1.3 Dipeptidylpeptidase-4 inhibitors (gliptins)
|
Sitagliptin is the first line/preferred cost-effective gliptin. Sitagliptin is first line for all eligible patients/new initiations. Where existing patients are prescribed a different gliptin, and ongoing prescribing of a gliptin is indicated following diabetes review, switch to generic sitagliptin if appropriate.
| Pack | Price |
|---|---|
| 28 tablet | £3.06 |
| Pack | Price |
|---|---|
| 28 tablet | £3.52 |
| Pack | Price |
|---|---|
| 100 tablet | |
| 28 tablet | £3.66 |
Documents
-
Primary Care
-
Secondary Care
-
Primary and Secondary Care
Uploaded By:
Renewal: 02/2027
Approved: 12/2024
Last Reviewed: 12/2024
Document linked to:
| Drug | Section |
|---|---|
| Linagliptin |
6.3.1.3 Dipeptidylpeptidase-4 inhibitors (gliptins)
|
| Sitagliptin (Generic) |
6.3.1.3 Dipeptidylpeptidase-4 inhibitors (gliptins)
|
Sitagliptin is the first line/preferred gliptin. Linagliptin is the second line gliptin to be used only after sitagliptin has been tried, or if eGFR <45ml/min/1.73m2.
| Pack | Price |
|---|---|
| 28 tablet | £33.26 |
| 30 tablet |
Sitagliptin is the first line/preferred cost-effective gliptin. Where existing patients are prescribed alogliptin, and ongoing prescribing of a gliptin is indicated following next diabetes review, switch to generic sitagliptin if appropriate.
| Pack | Price |
|---|---|
| 28 tablet | £26.60 |
| Pack | Price |
|---|---|
| 28 tablet | £26.60 |
| Pack | Price |
|---|---|
| 28 tablet | £26.60 |
| Pack | Price |
|---|---|
| 56 tablet | £33.26 |
| Pack | Price |
|---|---|
| 56 tablet | £33.26 |
| 60 tablet |
| Pack | Price |
|---|---|
| 28 tablet | £31.60 |
| Pack | Price |
|---|---|
| 28 tablet | £31.60 |
| Pack | Price |
|---|---|
| 60 tablet | £35.68 |
| Pack | Price |
|---|---|
| 60 tablet | £35.68 |